8-K: Scilex Subsidiary Semnur Announces $2 Billion Business Combination with Denali Capital Acquisition Corp.

Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, has signed a letter of intent for a business combination with Denali Capital Acquisition Corp., valuing Semnur at up to $2 billion.

Summary

• Scilex Holding Company's subsidiary, Semnur Pharmaceuticals, has entered into a letter of intent for a potential business combination with Denali Capital Acquisition Corp. (DECA).
• The proposed deal values Semnur at up to $2 billion, subject to a third-party fairness opinion.
• The transaction is expected to provide Semnur with up to $40 million in cash, depending on SPAC share redemptions.
• The merger aims to create a publicly traded biopharma company focused on developing non-opioid pain treatments.
• The primary focus of the combined entity will be the development of SP-102 (SEMDEXA), a Phase 3 non-opioid treatment for sciatica.
• Scilex is expected to be the majority shareholder of the combined company.
• Semnur's lead product, SP-102, has completed a Phase 3 trial showing significant pain reduction and improved disability scores in sciatica patients.
• Market research projects peak annual sales for SP-102 to reach up to $3.6 billion within five years of launch.
• The U.S. has over 30 million people with low back and radicular pain, highlighting a significant market opportunity.
• The combined company is expected to be named Semnur Pharmaceuticals, Inc. and will be led by the current management teams of Scilex and Semnur.

Sentiment

Score: 8

Explanation: The document is very positive, highlighting a significant business combination, strong market potential for SP-102, and positive clinical trial results. The management commentary is also optimistic. However, there are risks associated with the deal not being completed and the uncertainty of the final valuation.

Positives

• The proposed business combination provides significant capital for the development of SP-102.
• SP-102 has demonstrated positive Phase 3 trial results, showing significant pain reduction and improved disability scores.
• The market potential for SP-102 is substantial, with projected peak sales of up to $3.6 billion annually.
• The combined company will be led by experienced management teams from Scilex and Semnur.
• SP-102 has received FDA Fast Track status, potentially accelerating its approval process.
• The deal will create a publicly traded biopharma company focused on non-opioid pain management.

Negatives

• The deal is subject to a definitive merger agreement, board approvals, and shareholder approval, with no guarantee of completion.
• The pre-transaction equity value of Semnur is subject to adjustment based on a third-party fairness opinion.
• The expected cash on hand at closing is dependent on the number of SPAC shares redeemed, which could be lower than $40 million.
• The transaction is complex and involves multiple steps, including SEC filings and shareholder votes, which could introduce delays or complications.

Risks

• There is no assurance that a definitive merger agreement will be reached or that the proposed transaction will be completed.
• The transaction is subject to various approvals and conditions, including shareholder approval, which may not be obtained.
• The final valuation of Semnur could be adjusted based on a third-party fairness opinion.
• The amount of cash available at closing is dependent on SPAC share redemptions, which are uncertain.
• The combined company's success depends on the successful development and commercialization of SP-102, which is not guaranteed.
• The market for pain management therapies is competitive, and there is no guarantee that SP-102 will achieve its projected sales potential.
• The company is subject to regulatory risks, including the risk that SP-102 may not receive FDA approval.

Future Outlook

The combined company expects to capitalize on Semnur's product candidate, SP-102, and anticipates seeking shareholder approval in the second half of 2024. The company also expects to file a registration statement on Form S-4 with the SEC.

Management Comments

• Jaisim Shah, CEO of Scilex, stated that this is an important milestone in unlocking the value of SP-102 and thanked the team for their work.
• Lei Huang, CEO of Denali Capital Acquisition Corp., expressed excitement about the potential of SP-102 and the opportunity to work with the Semnur team.

Industry Context

This announcement reflects a growing trend in the biopharmaceutical industry where companies are seeking to develop and commercialize non-opioid pain management solutions due to the opioid crisis and the need for safer alternatives. The merger with a SPAC is a common method for private companies to go public and raise capital.

Comparison to Industry Standards

• The projected peak sales of $3.6 billion for SP-102 are ambitious but not unprecedented for successful pain management drugs.
• Companies like Pacira BioSciences (PCRX) with its non-opioid pain medication EXPAREL, have demonstrated the potential for significant revenue in this market.
• The use of a SPAC for a merger is a common route for biotech companies to go public, similar to how companies like 23andMe (ME) and Ginkgo Bioworks (DNA) have entered the public markets.
• The focus on a non-opioid treatment for sciatica aligns with the industry's shift away from opioid-based pain management, similar to the development of non-opioid alternatives by companies like Heron Therapeutics (HRTX).

Stakeholder Impact

• Shareholders of Scilex are expected to benefit from the potential value creation through the business combination and the development of SP-102.
• Patients suffering from sciatica may benefit from a new non-opioid treatment option if SP-102 is successfully developed and approved.
• Employees of Semnur and Scilex may experience changes in their roles and responsibilities as a result of the merger.
• The merger could impact the competitive landscape for pain management therapies, potentially affecting other companies in the industry.

Next Steps

• Negotiation of a definitive merger agreement between Semnur and Denali Capital Acquisition Corp.
• Approval of the merger agreement by the boards of directors of both companies.
• Satisfaction of the conditions negotiated in the proposed merger agreement.
• Approval of the proposed transaction by the SPAC's shareholders.
• Filing of a registration statement on Form S-4 with the SEC, including a proxy statement/prospectus.
• Seeking approval from the SPAC's shareholders in the second half of 2024.

Key Dates

Keywords

Semnur Pharmaceuticals, Scilex Holding Company, Denali Capital Acquisition Corp, SP-102, SEMDEXA, business combination, merger, non-opioid pain management, sciatic pain, FDA Fast Track, biopharma, special purpose acquisition company, SPAC